MetaVia Inc.

Metavia Inc.

Biotechnology • Healthcare • Cambridge, MA, United States • MTVA (NCM)

MetaVia Inc., a clinical-stage biotechnology company, focuses on developing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, as well as completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in Phase 1 trial for the treatment of obesity. The company's therapeutic programs include ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 for the treatment of cognitive impairment; and Gemcabene for the treatment of dyslipidemia. It has a license agreement with Pfizer Inc. for the research, development, manufacture, and commercialization of Gemcabene; and Dong-A ST, a sole manufacturer for the production of DA-1241 and DA-1726. The company was formerly known as NeuroBo Pharmaceuticals, Inc. and changed its name to MetaVia Inc. in November 2024. MetaVia Inc. is headquartered in Cambridge, Massachusetts. MetaVia Inc. operates as a subsidiary of Dong-A ST Co., Ltd.

857 702 9600 545 Concord Avenue, Cambridge, MA 02138, United States

Stock Performance (90 Days)

Data through Dec 30, 2025
Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

MetaVia Inc. Announces 1-for-11 Reverse Stock Split - PR Newswire
PR Newswire • Dec 2
MetaVia Reports Third Quarter 2025 Financial Results and Provides Corporate Update - PR Newswire
PR Newswire • Nov 6
MetaVia Inc. (MTVA) Stock Jumps After Reverse Split: What the New Price, Trial Data and 2026 Forecast Mean for Investors - ts2.tech
ts2.tech • Dec 6
MTVA Stock Soars as Analysts Weigh In - StocksToTrade
StocksToTrade • Nov 5
We're Keeping An Eye On MetaVia's (NASDAQ:MTVA) Cash Burn Rate - Yahoo Finance
Yahoo Finance • Sep 17

Other Biotechnology Companies

View All →
CODEXIS, INC. logo Codexis, Inc.
1 layoff tracked
$144.5M market cap
VERTEX PHARMACEUTICALS INC / MA logo Vertex Pharmaceuticals Inc. / MA
$118.68B market cap
REGENERON PHARMACEUTICALS, INC. logo Regeneron Pharmaceuticals, Inc.
$82.72B market cap
ALNYLAM PHARMACEUTICALS, INC. logo Alnylam Pharmaceuticals, Inc.
$52.92B market cap
ARGENX SE logo Argenx SE
$52.62B market cap
INSMED Inc logo Insmed Inc.
$37.61B market cap

Frequently Asked Questions

Has MetaVia Inc. had layoffs?
No layoff events have been recorded for MetaVia Inc. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.
How many employees does MetaVia Inc. have?
MetaVia Inc. has approximately 9 employees.
What industry is MetaVia Inc. in?
MetaVia Inc. operates in the Biotechnology industry, within the Healthcare sector.
Is MetaVia Inc. a publicly traded company?
Yes, MetaVia Inc. is publicly traded under the ticker symbol MTVA on the NCM. The company has a market capitalization of approximately $0.02 billion.
Where is MetaVia Inc. headquartered?
MetaVia Inc. is headquartered in Cambridge, MA, United States at 545 Concord Avenue, Cambridge, MA 02138, United States.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.